FDAapproval83% confidence
FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer
Source: FDA
Why This Matters
Why this matters: sets a approval precedent in the same sub-indication (breast cancer) as AstraZeneca.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · ER-positive Breast Cancer
- Sub-indication
- Breast Cancer
Related signal: Camizestrant Recommended for 1st-Line ER-Positive Breast Cancer in EU